CoChat

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors

Open access
Smith, Amanda M., Dun, Matthew D., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan, Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop, Verrills, Nicole M. · 2016 · Oncotarget
Cited by 51

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Amanda M. Smith 1, 2, 3, * , Matthew D. Dun 1, 2, * , Erwin M. Lee 4 , Celeste Harrison 1, 2 , Richard Kahl 1, 2 , Hayley Flanagan 1, 2 , Nikita Panicker 1, 2 , Baratali Mashkani 1, 2, 5 , Anthony S. Don 6 , Jonathan Morris 7 , Hamish Toop 7 , Richard B. Lock 4 , Jason A. Powell 8 , Daniel Thomas 8, 9 , Mark A. Guthridge 10 , Andrew Moore 11 , Leonie K. Ashman 1, 2 , Kathryn A. Skelding 1, 2 , Anoop Enjeti 1, 2, 12 , Nicole M. Verrills 1, 2 1 School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia 2 Hunter Medical Research Institute, Newcastle, New South Wales, Australia 3 Current address: The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia 4 Children’s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW, Sydney, New South Wales, Australia 5 Current address: Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 6 Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia 7 School of Chemistry, University of New South Wales, Sydney, New South Wales, Australia 8 Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia 9 Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA 10 Department Clinical Haematology, Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia 11 Translational Research Institute, The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia 12 Calvary Mater Hospital, Newcastle, New South Wales, Australia * These authors contributed equally to this work Correspondence to: Nicole M. Verrills, email: nikki.verrills@newcastle.edu.au Keywords: PP2A, FTY720, AML, FLT3, tyrosine kinase inhibitor Received: April 07, 2016 Accepted: June 06, 2016 Published: June 18, 2016 ABSTRACT Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A). Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S). FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells. Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD + BaF3 and MV4-11 cell lines. PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts. Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits. AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes. Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD + cells. A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment. Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.10167

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Smith, A. M., Dun, M. D., Lee, E. M., Harrison, C., Kahl, R., Flanagan, H., Panicker, N., Mashkani, B., Don, A. S., Morris, J., Toop, H., Lock, R. B., Powell, J. A., Thomas, D., Guthridge, M. A., Moore, A., Ashman, L. K., Skelding, K. A., Enjeti, A., & Verrills, N. M.
Venue
Oncotarget
Published
2016-06-18
Volume
7
Issue
30
Pages
47465-47478
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2430824944
Cited by
51
References
7
FWCI
6.06
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.